Of possible interest

KEI requests that DHHS Inspector General investigate failure to disclose federal funding in Spinraza patents.

KEI objects to the U.S. Army grant of an exclusive license to Sanofi on U.S. Army-owned patents on a Zika Virus vaccine.

Research and testimony on transparency legislation.

Request to the NIH and U.S. Army to use government royalty free or march-in rights on the prostate cancer drug Xtandi.

Proposal for a WTO Agreement on the Supply of Public Goods.

Innovation inducement prizes as an alternative to IPR monopolies to reward successful innovation.

Now is a good time to donate money to KEI.

KEI timelines, on a variety of topics.


Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?:

13 non-profits urge Senate HELP Committee to block floor amendments to 21st Century Cures Act counterpart

Before the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) presents a legislative package of healthcare reforms to the Senate floor for an up-or-down vote, 13 consumer, patient and health non-profit groups sent a letter to HELP Chairman and Ranking Member to ensure that the final legislative package includes only those bills that the HELP Committee reviewed in mark-up sessions.

122 experts defend Colombia's right to issue compulsory license on imatinib in face of U.S. pressure

(More on Colombia here: http://keionline.org/colombia)

On May 16, 2016, 122 health, trade, and intellectual property experts defended the Colombian government's right to issue a compulsory license on imatinib, an expensive leukemia drug that is being sold at a high price by the Swiss drug company Novartis, in a letter to Colombian President Juan Manuel Santos.

2016: AAV­Mediated Aquaporin Gene Transfer To Treat Sjögren's Syndrome

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses

May 16th, 2016

Sally Hu, Ph.D., M.B.A.,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and Innovation Access,
National Institute of Dental and Craniofacial Research,
National Institutes of Health,
BLDG 1 DEM, RM667, 6701 Democracy Blvd.,
Bethesda, MD 20817
Telephone: (301) 594-2616
Facsimile: (301) 496-1005
Email: sally.hu@nih.gov.

WHO donors in 2015 (US, UK, Gates Foundation, GAVI Alliance, National Philanthropic Trust): Setting the agenda for global public health?

In the run up to the 69th World Health Assembly, to be convened in Geneva from 23 May 2016 to 28 May 2016, the World Health Organization (WHO) has prepared a document (A69/INF./3, 13 May 2016) entitled Voluntary contributions by fund and by contributor, 2015. Total voluntary contributions to WHO in 2015 amounted to $1,836,970,206 which represented a dip from the 2014 figure of $2,001,13,247.

SCCR32 Day 4 Strong statement on education by the American University PIJIP


Speaking on behalf of the American University programme on information justice and Intellectual Property. And I speak as an educator myself and also on behalf of a larger network that I coordinate called the global expert network on user rights which is a network of educators.

April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents

Update: english translation of letter now available at end this blog.

SCCR 32 KEI on Orphan Works

keiorphan.jpgKEI Statement SCCR 32 Day 4 on "Orphan works" and Libraries and Archives

I will be speaking here as a user of libraries and archives and as a user of out of print and orphan works for my past academic work and my research today.

April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license

(More on Colombia here: http://keionline.org/colombia)

Updated to include English translation of letter. Note that KEI also has copy of the letter of April 28, 2016, reporting on the meeting with Eissenstat here.

Fundación Karisma at WIPO SCCR32 on broadcast treaty


Good afternoon, and thank you very much, sir.
I wanted to refer to the rights to be granted in this proposed treaty and I would like to give you an example of something that has recently happened in Colombia and how sometimes the retransmission rights can be abused.

KEI Comments to DHHS on WHA 69 re CEWG, Nocommunicable Diseases

Today the Department of Health and Human Services held their annual WHA listening session. This year HHS sent an email the day prior announcing that the usual 3 minute allotment would be cut in half to 90 seconds. This decision caused several NGOs to not attend.

2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds

More on NIH licensing at http://keionline.org/nih-licenses

May 4, 2016

Betty Tong, Ph.D.
Senior Licensing and Patenting Manager
Technology Advancement Office
National Institute of Diabetes and Digestive and Kidney Diseases
12A South Drive,
Bethesda, MD 20892
Via email: betty.tong@nih.gov

May 4, 2016

Dear Dr. Betty Tong,

Xtandi patient on Medicare — with supplement — pays $441.97 per month

Astellas has claimed that patients taking Xtandi face very small co-payments. One patient living in Arizona contacted KEI with proof that Astellas' claims just aren't true. The patient, who is on Medicare, provided a copy of a summary of his expenses for the first quarter of of 2016.

His monthly patient co-payment is $441.97 a month.

Syndicate content